Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Up 284.8% in May

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) saw a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 79,267 shares, a growth of 284.8% from the April 30th total of 20,598 shares. Based on an average daily volume of 61,665 shares, the short-interest ratio is presently 1.3 days. Currently, 0.0% of the company’s stock are short sold.

Otsuka Price Performance

Shares of OTSKY opened at $36.51 on Friday. The firm has a market capitalization of $39.22 billion and a PE ratio of 15.41. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The company’s 50-day moving average is $34.91 and its 200-day moving average is $31.82. Otsuka has a fifty-two week low of $21.68 and a fifty-two week high of $37.52.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Equities analysts forecast that Otsuka will post 1.99 EPS for the current year.

Wall Street Analysts Forecast Growth

OTSKY has been the subject of several recent research reports. Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.